课题基金 / 基金详情

Data to Clinical Action: Using Predictive Analytics to Improve Care of Veterans with Opioid Use Disorder

Data to Clinical Action: Using Predictive Analytics to Improve Care of Veterans with Opioid Use Disorder
数据到临床行动:使用预测分析来改善对患有阿片类药物使用障碍的退伍军人的护理
批准号:
10317224
负责人:
Corey J Hayes
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2027-03-31
关键词:
AddressAreaArtificial IntelligenceAutomobile DrivingBig DataBig Data MethodsBuprenorphineBusinessesCaringClinicalComputersCounselingDataData AnalyticsData ScienceDiagnosisDiscriminationDoseDrug usageEffectivenessElectronic Health RecordEnrollmentEnsureFeasibility StudiesFocus GroupsFrequenciesFutureGuidelinesHealth Services AccessibilityHealthcareHybridsIndividualInformaticsIntelligenceInterventionK-Series Research Career ProgramsKnowledgeLearningLogistic RegressionsMeasuresMental HealthMethadoneMethodologyMethodsModelingMonitorNaltrexoneOpioidOutcomeOverdosePainPain managementPatientsPersonsPharmaceutical PreparationsPharmacy facilityPredictive AnalyticsPrimary Health CareProbabilityProviderRandomized Controlled TrialsReportingResearchResearch PriorityResourcesRiskRisk FactorsSamplingServicesSiteSubstance Use DisorderSuicideTechniquesTestingTimeTrainingTranslatingVeteransVisitacceptability and feasibilityarmbasebig-data sciencecare outcomescare systemscareerclinical decision supportcomorbiditydata warehousedesigneffectiveness evaluationeffectiveness testingexperiencefeasibility testingfeedforward neural networkfollow-uphigh riskillicit drug useimplementation scienceimprovedimproved outcomeinnovationinterestmachine learning methodmathematical modelmedical specialtiesmilitary veteranmodifiable riskmortalityneural networkoperationopioid overdoseopioid use disorderoverdose riskpeer supportpilot testpilot trialpredictive modelingpreventrandom forestskillsstandard of caresupport toolstooltreatment guidelinestreatment planningusabilitywaiver

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Background. Medication for opioid use disorder (MOUD) prevents overdoses and improves mortality in Veterans with OUD, but retention on MOUD is critical for achieving those clinical endpoints. Only 50% of Veterans are retained on MOUD at 6-months post-MOUD initiation. Poor engagement in additional needed care services is an important risk factor for early MOUD discontinuation. Consequently, providers’ ability to identify Veterans in need of additional care or support while on MOUD may increase the likelihood of Veterans’ continued use of MOUD. Valid predictive models can provide an accurate probability of an individual Veteran experiencing the outcome being modeled (e.g., MOUD discontinuation). Prediction of future MOUD discontinuation risk could provide an innovative and real-time method for identifying Veterans in need of additional care (e.g., peer support). Significance/Impact. Predictive models could be used to lower MOUD attrition risk and improve outcomes for this Veteran population by continuously monitoring their risk of MOUD discontinuation in real-time during active MOUD treatment and identifying those Veterans in need of additional care (e.g., if increasing risk between visits, providers might add peer support services to a treatment plan). Innovation. This CDA-2 encompasses three HSR&D research priority areas (opioid/pain, health care informatics, and access to care) while crosscutting HSR methods of “big” data and implementation science, all in an effort to improve care and outcomes for Veterans with OUD. This study will also be the first to develop and pilot test a clinical decision support tool (CDST), based on a predictive model, to improve Veterans’ MOUD retention. Specific Aims. (1) To develop and validate PREMMOUD, a PREdictive Model for MOUD discontinuation. Hypotheses: (H1) I will develop a predictive model with good discrimination (e.g., c-statistic, a measure of goodness-of-fit, ≥0.8) for identifying Veterans likely to discontinue MOUD within the initial 6 months of treatment; (H2) the model generated using neural network techniques will have better discrimination than the models generated using random forest and logistic regression techniques. (2) To adapt PREMMOUD into a CDST to continuously monitor risk of MOUD discontinuation and provide clinical guidelines for addressing the primary risk factors driving the PREMMOUD score. (3) To assess (a) the feasibility of conducting a large scale, randomized controlled trial (RCT) to test PREMMOUD CDST’s (P-CDST) effectiveness as well as (b) P- CDST’s acceptability among waivered providers. Hypotheses: (H3) The feasibility of conducting a large-scale RCT to evaluate P-CDST’s effectiveness will be supported; (H4) P-CDST will be acceptable among VHA waivered providers. Methodology. Using machine-learning methods and data from the VHA Corporate Data Warehouse (2006-2019), I will train and validate PREMMOUD in a national sample of Veterans initiating MOUD (Aim 1). For Aim 2, I will conduct two rounds of focus groups with key stakeholders (VHA providers, Veterans receiving MOUD, VHA operations partners) to inform the creation of a beta-version of P-CDST to be integrated into CPRS/Cerner. To build P-CDST, I will use VHA CDW data, PREMMOUD, SQL Server Reporting Services (SSRS) and the Business Intelligence Service Line (BISL) platform. P-CDST will contain the patient’s real-time PREMMOUD score as well as clinical guidelines to support the provider in addressing the Veteran’s specific risk factors driving the PREMMOUD score. For Aim 3, I will conduct a single-arm, two- site pilot trial to assess study feasibility (provider enrollment, frequency of P-CDST use, and follow-up rates) and P-CDST’s acceptability (clinical usability of P-CDST). Implementation/Next Steps. Aim 1 will support an HSR&D IIR submission in Year 3 to assess whether PREMMOUD can be used to identify which Veterans, receiving MOUD, can effectively be treated in specialty care versus non-specialty care and which Veterans benefit from additional supportive services. A second IIR proposal will be submitted post CDA-2 to conduct an RCT, using a hybrid design, to evaluate the effectiveness and implementation potential of P-CDST in VHA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: